Wolf Theiss advises Fareva on the acquisition of a production site of the Novartis Group

Vienna, 22 April 2021 – EBEWE Pharma, a Novartis Group company, has agreed with Fareva SA to acquire its production site in Unterach (Upper Austria). Together with the French law firm Darrois, Wolf Theiss advised Fareva, a leading contract service provider in the pharmaceutical sector, on the negotiation of the purchase agreement as well as the ancillary agreements. The Closing took place on March 31.

The Wolf Theiss Team consisted of Consultant Melanie Dimitrov/Tax, Partner Christian Hoenig/Corporate/M&A and Partner Karl Binder/Real Estate & Construction.

Fareva is a leading contract service provider in the industrial sector and offers, among other things, research, manufacturing and packaging solutions for the pharmaceutical industry. With the acquisition of the site in Unterach, Fareva will further strengthen its presence in the European market, especially in the area of ready-to-inject pharmaceuticals manufacturing. The site is considered a centre of excellence for the manufacture of injectable cancer drugs and will continue to produce for the Novartis Group. A corresponding supply agreement is part of the contractual agreement.